Hansa Biopharma AB represents a set of core values and a corporate philosophy focused on innovation, patient-centricity, and scientific excellence. As a leading biopharmaceutical company, Hansa Biopharma prioritizes the development of novel immunomodulatory enzyme therapies to improve the lives of patients with rare immunological conditions and transplants. The company's commitment to delivering innovative solutions and addressing unmet medical needs characterizes its corporate philosophy. Hansa Biopharma is dedicated to advancing scientific knowledge and forging strategic collaborations to drive drug discovery and development in the field of immunology.

Hansa Biopharma AB is primarily present in several countries and regions. The company operates in Europe, including Scandinavia, where it is headquartered in Sweden. Additionally, their presence extends to the United States, where they have established operations to cater to the American market. Hansa Biopharma AB's global reach indicates their commitment to expanding and serving diverse markets.

Some significant milestones achieved by Hansa Biopharma AB include the FDA approval of its lead drug candidate, IdeS, for the treatment of kidney transplantation, the initiation of Phase 2 clinical trials for a potential treatment of anti-GBM antibody disease, successful completion of an IPO to strengthen financial resources, and establishment of strategic partnerships with top biotechnology companies. Hansa Biopharma AB continues to advance its innovative therapies and expand its pipeline, focusing on developing targeted immunomodulatory treatments for rare autoimmune conditions and transplant rejection.

Hansa Biopharma AB, a leading biopharmaceutical company, has a rich history and background. Founded in 2001 and headquartered in Lund, Sweden, Hansa Biopharma specializes in developing innovative immunomodulatory treatments for patients with rare autoimmune diseases and transplant rejection. The company's mission is to improve the lives of patients by addressing unmet medical needs. With a strong focus on research and development, Hansa Biopharma has successfully brought forward novel therapies such as imlifidase, a unique enzyme used in kidney transplantation. Through its dedication to scientific excellence and commitment to patients, Hansa Biopharma has established itself as a trusted player in the biopharmaceutical industry.

Hansa Biopharma AB faces competition from several companies in the market. Some of its main competitors include Bristol-Myers Squibb, Johnson & Johnson, and Novartis. These companies operate in the biopharmaceutical industry and offer similar products and services as Hansa Biopharma AB. By providing innovative therapies and solutions, Hansa Biopharma AB aims to gain a competitive edge in the market and expand its market share.

Hansa Biopharma AB is primarily active in the biopharmaceutical industry.

The business model of Hansa Biopharma AB focuses on the development and commercialization of innovative immunomodulatory treatments for rare autoimmune conditions and transplant rejection. The company utilizes its proprietary technology platform, IdeS, which is designed to remove immunogenicity from biologic drugs, enhancing their safety and efficacy. With a commitment to addressing significant unmet medical needs, Hansa Biopharma leverages strategic collaborations and partnerships to advance its pipeline and bring life-changing therapies to patients. By combining scientific expertise with a patient-centric approach, the company aims to improve the lives of individuals with severe and debilitating diseases.

De K/W-verhouding kan momenteel niet worden berekend voor Hansa Biopharma.

De KUV kan momenteel niet worden berekend voor Hansa Biopharma.

De AlleAktien Kwaliteitsscore voor Hansa Biopharma is 8/10.

De verwachte Hansa Biopharma omzet is 316,45 mln. SEK.

De verwachte Hansa Biopharma winst is -613,31 mln. SEK.

Hansa Biopharma AB is a Swedish biotechnology company specializing in the research and development of therapies for rare immune diseases. Founded in 2004, the company focuses on developing therapeutics for the treatment of autoimmune diseases, where the body's immune system mistakenly attacks healthy cells. Hansa Biopharma's business model is based on the discovery, development, and commercialization of therapies for rare diseases. The company specializes in the development of highly specialized technologies and platforms for antibody modification. These technologies allow the company to develop novel therapeutics for specific indications. Hansa Biopharma's products include two main products. The first is Idefirix, a medication for the treatment of acute antibody-mediated rejection of kidney transplants in patients with high immune reactivity. Idefirix has been approved by the European Commission and is currently marketed in Europe. The second product is IdeS, a proteolytic enzyme developed for the removal of antibodies from the blood of patients with high immune reactivity. IdeS is still in clinical development. Hansa Biopharma has also entered into partnerships with other pharmaceutical companies to utilize its technologies and platforms for the development of therapeutics for other indications. Some of these partnerships include: - CSL Behring: Collaboration for the development of novel antibodies for the treatment of hemophilia - Sarepta Therapeutics: Development of novel antibodies for the treatment of Duchenne muscular dystrophy - AXIS Clinicals Limited: Marketing of Idefirix in India and other Asian countries Overall, Hansa Biopharma's business model is based on the combination of research and development of new therapeutics for specific indications and collaboration with other pharmaceutical companies to leverage its technologies for the development of new therapeutics for other diseases. As the company continues to invest in the clinical development of its products, Hansa Biopharma is expected to focus on expanding its product line and expanding its reach into new geographical regions. The company will also continue to utilize its capabilities in the development of technologies and platforms for antibody modification to maximize its competitive advantage in this growing area of pharmaceutical research.

Hansa Biopharma keert een dividend van 0 SEK uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Hansa Biopharma of het bedrijf keert geen dividend uit.

De ISIN van Hansa Biopharma is SE0002148817.

Het WKN van Hansa Biopharma is A0M65T.

De ticker van Hansa Biopharma is HNSA.ST.

Binnen de laatste 12 maanden betaalde Hansa Biopharma een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Hansa Biopharma naar verwachting een dividend van 0 SEK betalen.

De dividendrendement van Hansa Biopharma is momenteel .

Hansa Biopharma betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Hansa Biopharma betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 SEK verwacht. Dit komt overeen met een dividendrendement van 0 %.

Hansa Biopharma wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Hansa Biopharma van 27-6-2025 ter hoogte van 0 SEK te ontvangen, moest je het aandeel voor de ex-datum op 27-6-2025 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 27-6-2025.

In het jaar 2024 heeft Hansa Biopharma 0 SEK aan dividenden uitgekeerd.

De dividenden van Hansa Biopharma worden in SEK uitgekeerd.